Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.

2006679 citationsJournal Article

Authors

Lalitha Shankar · National Institutes of Health

John M. Hoffman · Huntsman Cancer Institute

S.L. Bacharach · University of California, San Francisco

Michael M. Graham · University of Iowa

Joel S. Karp

Adriaan A. Lammertsma · Vrije Universiteit Amsterdam

Steven M. Larson · Memorial Sloan Kettering Cancer Center

Abstract

Many therapeutic clinical trials have proposed using a measure of metabolic change to assess therapeutic response rather than relying on conventional anatomic measurements of changes in tumor size on CT or MRI. PET assessment of changes in 18F-FDG uptake by tumors is gaining acceptance as such a

Topics & Keywords

Medical Imaging Techniques and Applications Radiomics and Machine Learning in Medical Imaging Cancer, Hypoxia, and Metabolism

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: PubMed

Volume 47, Issue 6, pp. 1059-66